BenchSci

FEBRUARY 8, 2024

Earlier this month, I traveled across North America and the UK to meet our 340 team members. Every year in January, we kick off the year with our “Roadshow”, where I meet our team in person and share our accomplishments and learning from the previous year and where we are going next.

Pharma R&D 59

Pharma R&D Disease Drugs 59

BenchSci

MARCH 6, 2024

This surge has demonstrated to budget holders and decision-makers alike the significant impact AI can have when effectively applied, offering immense potential to accelerate drug discovery and development across various stages, from unraveling the complexity of disease biology to refining drug design and expediting clinical trials.

Pharma R&D 52

Pharma R&D Clinical Trials Pharmaceuticals Trials 52

Drug Discovery World

AUGUST 7, 2024

Within the next five to 10 years, AI will fundamentally change the way drugs are designed, with the potential to produce an order of magnitude for more high-quality candidates against a broad range of new diseases.

Pharma R&D 173

Pharma R&D Clinical Trials Pharma Companies Trials 173

The Pharma Data

JANUARY 10, 2021

Boehringer Ingelheim is significantly increasing its investment in a broad range of digital technologies, encompassing key areas such as Artificial Intelligence (AI), machine learning, and data science to better understand diseases, their drivers and biomarkers, and digital therapeutics.

Pharma R&D 40

Pharma R&D Pharmaceuticals Pharmaceutical Companies Disease 40